Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials
Work
Year: 2018
Type: article
Abstract: Late-onset toxicity is common for novel molecularly targeted agents and immunotherapy. It causes major logistic difficulty for existing adaptive phase I trial designs, which require the observance of ... more
Source: Clinical Cancer Research
Institutions The University of Texas MD Anderson Cancer Center, Northeast Normal University, Neoleukin Therapeutics (United States), Center for Drug Evaluation and Research, United States Food and Drug Administration +2 more
Cites: 25
Cited by: 104
Related to: 10
FWCI: 7.593
Citation percentile (by year/subfield): 99.98
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze
Funder National Cancer Institute
Grant ID P50CA098258